Prednisolone-loaded PLGA microspheres. In vitro characterization and in vivo application in adjuvant-induced arthritis in mice

AAPS PharmSciTech

Volumn 11, Issue 2, 2010, Pages 859-869

  Khaled, Khaled A ^a   Sarhan, Hatem A ^a   Ibrahim, Mohamed Abbas ^b   Ali, Azza H ^c   Naguib, Youssef W ^a  

^a Minia University   (Egypt)

^b KING SAUD UNIVERSITY   (Saudi Arabia)

^c Minia University   (Egypt)

Author keywords

Adjuvant arthritis; Histological investigation; Microspheres; PLGA; Prednisolone

Indexed keywords

FREUND ADJUVANT; MICROSPHERE; POLYGLACTIN; PREDNISOLONE; ANTIINFLAMMATORY AGENT; DRUG CARRIER; LACTIC ACID; MICROCAPSULE; POLYGLYCOLIC ACID; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER;

ADJUVANT ARTHRITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANKLE; ARTICLE; BIODEGRADABILITY; BONE EROSION; CELL INFILTRATION; CONTROLLED STUDY; DRUG RELEASE; ENCAPSULATION; FEMALE; GLASS TRANSITION TEMPERATURE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PARTICLE SIZE; PATIENT COMPLIANCE; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPY; SUSTAINED RELEASE FORMULATION; ANIMAL; ARTHRITIS; CHEMICALLY INDUCED; CHEMISTRY; DIFFUSION; DRUG FORMULATION; MICROCAPSULE; PROCEDURES; SYNTHESIS; TREATMENT OUTCOME;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ARTHRITIS; CAPSULES; DIFFUSION; DRUG CARRIERS; DRUG COMPOUNDING; FEMALE; FREUND'S ADJUVANT; LACTIC ACID; MICE; POLYGLYCOLIC ACID; PREDNISOLONE; TREATMENT OUTCOME;

EID: 77954818225     PISSN: None     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/s12249-010-9445-5     Document Type: Article

References (45)

1. Bao L, Zhu Y, ElHassan AM, Wu Q, Xiao B, Zhu J, et al. Adjuvant-induced arthritis: IL-1â, IL-6 and TNF-α are upregulated in the spinal cord. Neuroimmunology (Neuroreport). 2001;12(18):3905-8.
2. Gauldie SD, McQueen DS, Clarke CJ, Chessell IP. A robust model of adjuvant-induced chronic unilateral arthritis in two mouse strains. J Neurosci Methods. 2004;139:281-91.
3. Rannou F, Francois M, Corvol MT, Berenbaum F. Cartilage breakdown in rheumatoid arthritis. Joint Bone Spine. 2006;73:29-36.
4. Mythilypriya R, Shanthi P, Sachdanandam P. Salubrious effect of kalpaamruthaa, a modified indigenous preparation in adjuvant induced arthritis in rats-a biochemical approach. Chem Biol Interact. 2008;173(2):148-58.
5. Kumar VL, Roy S, Schgal R, Padhy BM. A comparative study on the efficacy of rofecoxib in monoarticular arthritis induced by latex of Calotropis procera and Freund's complete adjuvant. Inflammopharmacol. 2006;14:17-21.
6. Zhang L, Li J, Yu S.-C., Jin Y, Lv X.-W., Zou Y.-H., et al. Therapeutic effects and mechanisms of total flavonoids of Turpinia arguta seen on adjuvant arthritis in rats. J Ethnopharmacol. 2008;116:167-72.
7. Ding CH, Li Q, Xiang ZY, Zhou AW, Jones G, Xu SY. Oral administration of type II collagen suppresses pro-inflammatory mediator production by synoviocytes in rats with adjuvant arthritis. Clin Exp Immunol. 2003;132:416-23.
8. Knight B, Katz DR, Isenberg DA, Ibrahim MA, LePage S, Huchings P, et al. Induction of adjuvant arthritis in mice. Clin Exp Immunol. 1992;90:459-65.
9. Chillingworth NL, Donaldson NF. Characterisation of a Freund's complete adjuvant-induced model of chronic arthritis in mice. J Neurosci Methods. 2003;128:45-52.
10. Bulej P, Kuchar M, Panajotova V, Jegorov A. Pharmacological profile of 4-(2',4'-difluorobiphenyl-4-yl)-2-methylbutyric acid (deoxoflobufen). Arzneimittelforschung. 2005;55(8):466-72.
11. Hildebrandt G, Jahns J, Hindemith M, Spranger S, Sack U, Kinne RW, et al. Effects of low dose radiation therapy on adjuvant induced arthritis in rats. Int J Radiat Biol. 2000;76(8):1143-53.
12. Hambleton P, McMahon S. Drug actions on delayed-type hypersensitivity in rats with developing and established adjuvant arthritis. Agents Actions. 1990;29(3/4):328-32.
13. Tachibana M, Inoue N, Yoshida E, Matsui M, Ukai Y, Yanu J. Anti-inflammatory effect and low ulcerogenic activity of etodolac, a cyclooxygenase-2 selective non-steroidal anti-inflammatory drug, on adjuvant-induced arthritis in rats. Pharmacology. 2003;68:96-104.
14. Palakurthi S, Vyas SP, Diwan PV. Biodisposition of PEG-coated lipid microspheres of indomethacin in arthritic rats. Int J Pharm. 2005;290:55-62.
15. Yordanov M, Deleva A, Ivanovska N. Host resistance against Candida albicans infection in mice with adjuvant induced arthritis. Mycopathologia. 2001;153:77-82.
16. Lundberg IE, Grundtman C, Larsson E, Klareskog L. Corticosteroids-from an idea to clinical use. Best Pract Res Clin Rheumatol. 2004;18(1):7-19.
17. Boers M. Glucocorticoids in rheumatoid arthritis: a senescent research agenda on the brink of rejuvenation? Best Pract Res Clin Rheumatol. 2004;18(1):21-9.
18. Barnes PJ. Corticosteroids: the drugs to beat. Eur J Pharmacol. 2006;533:2-14.
19. Adcock IM. Corticosteroids: limitations and future prospects for treatment of severe inflammatory disease. Drug Discov Today Ther Strat. 2004;1(3):321-8.
20. Vanniasinghe AS, Bender V, Manolios N. The potential of liposomal drug delivery for the treatment of inflammatory arthritis. Semin Arthritis Rheum. 2009;39(3):182-96.
21. Wolfe F. The epidemiology of drug treatment failure in rheumatoid arthritis. Baillières Clin Rheumatol. 1995;9(4):619-32.
22. Smith A, Hunneyball I. Evaluation of poly (lactic acid) as a biodegradable drug delivery system for parenteral administration. Int J Pharm. 1986;30:215-20.
23. Khaled AK, Sarhan HA, Ibrahim MA, Naguib YW. Controlledrelease prednisolone poly (DL-lactide) microspheres: impact of formulation parameters, characterization and release mechanism. Bull Pharm Sci, Assiut Univ. 2008;31(1):49-67.
24. Redmon MP, Hickey AJ, DeLuca PP. Prednisolone-21-acetate (poly glycolic) acid microspheres: influence of matrix characteristics on release. J Control Release. 1989;9:99-109.
25. Esposito E, Meregatti E, Cortesi R. Hyaluronan-based microspheres for drug delivery: a comparative study. Int J Pharm. 2005;288:35-49.
26. Burgess DJ, Davis SS, Tomlinson E. Potential use of albumin microspheres as a drug delivery system. 1. Preparation and in vitro release of steroids. Int J Pharm. 1987;39:129-36.
27. Onishi H, Oosegi T, Machida Y, Ku S, McGinity JW. Preparation and in vitro evaluation of chitosan microspheres containing prednisolone: comparison of simple and conjugate microspheres. Drug Dev Ind Pharm. 2005;31:597-605.
28. Oosegi T, Onishi H, Machida Y. Gastrointestinal distribution and absorption behavior of Eudragit-coated chitosan-prednisolone conjugate microspheres in rats with TNBS-induced colitis. Int J Pharm. 2008;348:80-8.
29. Oosegi T, Onishi H, Machida Y. Novel preparation of entericcoated chitosan-prednisolone conjugate microspheres and in vitro evaluation of their potential as a colonic delivery system. Eur J Pharm Biopharm. 2008;68:260-6.
30. Brannon-Peppas L, Vert M. Polylactic and polyglycolic acids as drug delivery carriers. In: Wise D, editor. Handbook of pharmaceutical controlled release technology. New York: Marcel Dekker Inc.; 2000. p. 99-130.
31. Park S.-B., Jeon Y.-J., Haam S, Park H.-Y., Kim Y.-S. Preparation of chitosan microspheres using membrane emulsification and its size modeling. J Microencapsul. 2004;21(5):539-52.
32. Jeffery H, Davis SS, O'Hagan DT. The preparation and characterization of poly (lactide-co-glycolide) microparticles. I: Oil-in-water emulsion solvent evaporation. Int J Pharm. 1991;77:169-75.
33. Chen PC, Park YJ, Chang LC, Kohane DS, Bartlett RR, Langer R, et al. Injectable microparticle-gel system for prolonged and localized lidocaine release. I. In vitro characterization. J Biomed Mater Res A. 2004;70:412-9.
34. Luan X, Bodmeier R. Modification of the tri-phasic drug release pattern of leuprolide acetate-loaded poly (lactide-co-glycolide) microparticles. Eur J Pharm Biopharm. 2006;63:205-14.
35. Bodmeier R, McGinity JW. The preparation and evaluation of drug-containing poly (DL-lactide) microspheres formed by the solvent evaporation method. Pharm Res. 1987;4(6):465-71.
36. Martinez-Sancho C, Herrero-Vanrell R, Negro S. Poly (D, L-lactide-co-glycolide) microspheres for long-term intravitreal delivery of aciclovir: influence of fatty and non-fatty additives. J Microencapsul. 2003;20(6):799-810.
37. Siepmann J, Goepferich A. Mathematical modeling of bioerodible, polymeric drug delivery systems. Adv Drug Deliv Rev. 2001;48:229-47.
38. Arifin DY, Lee LY, Wang C.-H. Mathematical modeling and simulation of drug release from microspheres: implications to drug delivery systems. Adv Drug Deliv Rev. 2006;58:1274-325.
39. Lewis DH. Controlled release of bioactive agents from lactide/glycolide polymers. In: Chasin M, Langer R, editors. Biodegradable polymers as drug delivery systems. New York, USA: Marcel Dekker; 1990. p. 1-40.
40. Chen X, Ooi CP. Hydrolytic degradation and drug release properties of ganciclovir-loaded biodegradable microspheres. Acta Biomater. 2008;4(4):1046-56.
41. Blanco MD, Sastre RL, Teijon C, Olmo R, Teijon JM. Degradation behaviour of microspheres prepared by spraydrying poly (D, L-lactide) and poly (D, L-lactide-co-glycolide) polymers. Int J Pharm. 2006;326:139-47.
42. Park TG. Degradation of poly (lactic-co-glycolic acid) microspheres: effect of copolymer composition. Biomaterials. 1995;16:1125-30.
43. Blasi P, D'Souza SS, Selmin F, DeLuca PP. Plasticizing effect of water on poly (lactide-co-glycolide). J Control Release. 2005;108:1-9.
44. Klose D, Siepmann F, Elkharraz K, Siepmann J. PLGA-based drug delivery systems: importance of the type of drug and device geometry. Int J Pharm. 2008;354:95-103.
45. Blackham A, Burns JW, Farmer JB, Radziwonik H, Westwick J. An X-ray analysis of adjuvant arthritis in the rat. The effect of prednisolone and indomethacin. Agents Actions. 1977;71:145-51.